Patents Assigned to EMPIRICO INC.
  • GalNAc compositions for improving siRNA bioavailability
    Patent number: 11879125
    Abstract: Provided herein, are compositions comprising GaINAc moieties that may be conjugated to an oligonucleotide. The oligonucleotide may be a small interfering RNA or an antisense oligonucleotide. Also provided herein are methods of treatment that include administering the composition to a subject.
    Type: Grant
    Filed: March 15, 2023
    Date of Patent: January 23, 2024
    Assignee: EMPIRICO INC.
    Inventors: Darren H. Wakefield, David Rozema, Omri Gottesman
  • Prodrugs of ALOX-15 inhibitors and methods of using the same
    Patent number: 11666588
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: June 6, 2023
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • Treatment of thymic stromal lymphopoietin (TSLP) related diseases by inhibition of long-form TSLP transcripts
    Patent number: 11452738
    Abstract: Provided are compositions comprising an oligonucleotide that targets Thymic stromal lymphopoietin (TSLP). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating an airway disorder by providing an oligonucleotide that targets TSLP to a subject in need thereof. In some embodiments, the oligonucleotide targeting is specific for a long isoform of TSLP (1fTSLP).
    Type: Grant
    Filed: January 3, 2020
    Date of Patent: September 27, 2022
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • Oligonucleotides for treatment of angiopoietin like 4 (ANGPTL4) related diseases
    Patent number: 11377658
    Abstract: Provided are compositions comprising an oligonucleotide that targets Angiopoietin-like 4 (ANGPTL4). The oligonucleotide may include a small interfering RNA (siRNA) or an antisense oligonucleotide (ASO). Also provided herein are methods of treating a metabolic or cardiovascular disorder by providing an oligonucleotide that targets ANGPTL4 to a subject in need thereof.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: July 5, 2022
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • Prodrugs of ALOX-15 inhibitors and methods of using the same
    Patent number: 11116778
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: September 14, 2021
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Brian Cajes, David Lewis, David Rozema
  • Treatment of angiopoietin like 7 (ANGPTL7) related diseases
    Patent number: 10941404
    Abstract: Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: March 9, 2021
    Assignee: EMPIRICO INC.
    Inventors: Omri Gottesman, Shannon Bruse, Paul Buske, Brian Cajes, David Lewis, David Rozema